These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10215957)

  • 1. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk.
    Thorland EC; Drost JB; Lusher JM; Warrier I; Shapiro A; Koerper MA; Dimichele D; Westman J; Key NS; Sommer SS
    Haemophilia; 1999 Mar; 5(2):101-5. PubMed ID: 10215957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of anaphylactic shock in haemophilia B patients with inhibitors.
    Warrier I; Lusher JM
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S125-8. PubMed ID: 9819043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular genotyping of the Italian cohort of patients with hemophilia B.
    Belvini D; Salviato R; Radossi P; Pierobon F; Mori P; Castaldo G; Tagariello G;
    Haematologica; 2005 May; 90(5):635-42. PubMed ID: 15921378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor IX gene analysis in 70 unrelated patients with haemophilia B: description of 13 new mutations.
    Attali O; Vinciguerra C; Trzeciak MC; Durin A; Pernod G; Gay V; Ménart C; Sobas F; Dechavanne M; Négrier C
    Thromb Haemost; 1999 Nov; 82(5):1437-42. PubMed ID: 10595634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
    Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
    Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete deletion of factor IX gene and inhibition of factor IX activity in a labrador retriever with hemophilia B.
    Brooks MB; Gu W; Ray K
    J Am Vet Med Assoc; 1997 Dec; 211(11):1418-21. PubMed ID: 9394892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
    Parquet A; Laurian Y; Rothschild C; Navarro R; Guérois C; Gay V; Durin A; Peynet J; Sultan Y
    Thromb Haemost; 1999 Oct; 82(4):1247-9. PubMed ID: 10544907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of hemophilia B in North Indian families: identification of novel and recurrent molecular events in the factor IX gene.
    Mahajan A; Chavali S; Kabra M; Chowdhury MR; Bharadwaj D
    Haematologica; 2004 Dec; 89(12):1498-503. PubMed ID: 15590401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).
    Chitlur M; Warrier I; Rajpurkar M; Lusher JM
    Haemophilia; 2009 Sep; 15(5):1027-31. PubMed ID: 19515028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Methylation of the factor IX gene--a basic reason for the mutation causing hemophilia B].
    Mazin AL
    Mol Biol (Mosk); 1995; 29(1):71-90. PubMed ID: 7723765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectrum of factor IX gene mutations causing haemophilia B from India.
    Ghosh K; Quadros L; Shetty S
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):333-6. PubMed ID: 19357501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of factor IX mutations in Iranian haemophilia B patients by SSCP and sequencing.
    Karimipoor M; Zeinali S; Nafissi N; Tuddenham EG; Lak M; Safaee R
    Thromb Res; 2007; 120(1):135-9. PubMed ID: 17014892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pathology of haemophilia B: identification of five novel mutations including a LINE 1 insertion in Indian patients.
    Mukherjee S; Mukhopadhyay A; Banerjee D; Chandak GR; Ray K
    Haemophilia; 2004 May; 10(3):259-63. PubMed ID: 15086324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel missense mutation in the coagulation factor IX catalytic domain associated with severe haemophilia B--Factor IXDelhi.
    Mahajan A; Sharma A; Chavali S; Kabra M; Chowdhury MR; Srinivasan N; Bharadwaj D
    Haemophilia; 2004 Sep; 10(5):550-2. PubMed ID: 15357782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic risk factors for inhibitors to factors VIII and IX.
    Oldenburg J; Pavlova A
    Haemophilia; 2006 Dec; 12 Suppl 6():15-22. PubMed ID: 17123389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA analysis of seven patients with hemophilia B who have anti-factor IX antibodies: relationship to clinical manifestations and evidence that the abnormal gene was inherited.
    Tanimoto M; Kojima T; Kamiya T; Takamatsu J; Ogata K; Obata Y; Inagaki M; Iizuka A; Nagao T; Kurachi K
    J Lab Clin Med; 1988 Sep; 112(3):307-13. PubMed ID: 3411192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors in haemophilia B: the Italian experience.
    Castaman G; Bonetti E; Messina M; Morfini M; Rocino A; Scaraggi FA; Tagariello G;
    Haemophilia; 2013 Sep; 19(5):686-90. PubMed ID: 23601006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe haemophilia B due to a 6 kb factor IX gene deletion including exon 4: non-homologous recombination associated with a shortened transcript from whole blood.
    Hsu TC; Nakaya SM; Thompson AR
    Thromb Haemost; 2007 Feb; 97(2):176-80. PubMed ID: 17264943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence and structural properties of identical mutations with varying phenotypes in human coagulation factor IX.
    Chavali S; Sharma A; Tabassum R; Bharadwaj D
    Proteins; 2008 Oct; 73(1):63-71. PubMed ID: 18393396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
    Taki M; Shirahata A
    Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.